The pEg3 protein is a member of the evolutionarily conserved KIN1/PAR-1/MARK kinase family which is involved in cell polarity and microtubule dynamics. In Xenopus, pEg3 has been shown to be a cell cycle dependent kinase whose activity increases to a maximum level during mitosis of the first embryonic cell division. CDC25B is one of the three CDC25 phosphatase genes identified in human. It is thought to regulate the G2/M progression by dephosphorylating and activating the CDK/cyclin complexes. In the present study we show that the human pEg3 kinase is able to specifically phosphorylate CDC25B in vitro. One phosphorylation site was identified and corresponded to serine 323. This residue is equivalent to serine 216 in human CDC25C which plays an important role in the regulation of phosphatase during the cell cycle and at the G2 checkpoint. pEg3 is also able to specifically associate with CDC25B in vitro and in vivo. We show that the ectopic expression of active pEg3 in human U2OS cells induces an accumulation of cells in G2. This effect is counteracted by overexpression of CDC25B. Taken together these results suggest that pEg3 is a potential regulator of the G2/M progression and may act antagonistically to the CDC25B phosphatase.
Introduction
In vertebrates, the cell cycle is controlled by successive activation of cyclin-dependent kinases (CDKs). CDK1 kinase (CDC2) is the major regulator of cell entry into mitosis and has been conserved throughout evolution, since it is found from yeast to human. The activity of CDK1 is controlled at multiple levels by a variety of mechanisms including subunits association and phosphorylation (Morgan, 1997) . In yeast Schizosaccharomyces pombe, CDK1 is inhibited by phosphorylation on tyrosine 15 by Wee1/Mik1 kinase (McGowan and Russell, 1993; Russell and Nurse, 1987) . In higher eukaryotes, CDK1 is also inhibited by an additional phosphorylation on threonine 14 by the Myt1 kinase (Liu et al., 1997; Mueller et al., 1995) . The dual specific phosphatase CDC25 dephosphorylates and activates CDK1 (Gould and Nurse, 1989) .
In human, three CDC25 genes (CDC25A, B and C) have been identified (Galaktionov and Beach, 1991; Nagata et al., 1991; Sadhu et al., 1990) . CDC25A is required for entry of cells into S phase (Hoffmann et al., 1994; Jinno et al., 1994) likely by dephosphorylating G1/S specific CDK/cyclin E complexes. Both CDC25B and CDC25C are involved in the control of G2/M transition (Gabrielli et al., 1996; Lammer et al., 1998; Millar et al., 1991) . However functions of CDC25B and CDC25C do not overlap, since the CDC25B phosphatase activity peaks prior to CDC25C. Moreover CDC25B induces mitosis more efficiently than CDC25C (Karlsson et al., 1999) . How CDC25B functions in G2/M progression is not yet clear. Until recently most of the efforts have been concentrated on the regulation of CDC25C activity.
CDC25C is the substrate for several kinases and is involved in the DNA damage induced G2 arrest. DNA damage is followed by activation of a checkpoint which delays entry into mitosis by lengthening the G2 phase. The importance of serine at position 216 (S216) in CDC25C has been highlighted. CHK1 kinase, which is activated upon DNA damage, phosphorylates S216 (Peng et al., 1997; Sanchez et al., 1997) . The phosphorylated S216 residue constitutes a binding site for 14-3-3 protein (Peng et al., 1997) . Binding of 14-3-3 would prevent CDC25C nuclear localization (Dalal et al., 1999; Kumagai and Dunphy, 1999; Yang et al., 1999) then delaying CDK1/cyclin B activation and mitosis. S216 is also phosphorylated during interphase in the absence of DNA damage. The C-TAK1 kinase (CDC twenty five associated kinase 1) which was shown to associate with CDC25C, in vitro and in cells after transfection, is responsible for this phosphorylation (Peng et al., 1997 (Peng et al., , 1998 . It is assumed that S216 phosphorylation keeps CDC25C inactive during interphase by 14-3-3 binding.
The steady state level of CDC25B fluctuates during the cell cycle (Gabrielli et al., 1996) , the maximal amount of CDC25B being detected during G2/M. The CDK1/cyclin A complex phosphorylates the CDC25B protein and controls its proteasome dependent degradation (Baldin et al., 1997) hence regulating the amount of CDC25B during the cell cycle. The phosphatase activity of CDC25B is also cell cycle dependent reaching its maximal level from S phase to G2 phase (Lammer et al., 1998) . In human three splicing variants (CDC25B1, CDC25B2 and CDC25B3) have been identified (Baldin et al., 1997) . Until now only differences in the subcellular localization of CDC25B2 and CDC25B3 have been found (Woo et al., 1999) , however, these differences were not observed by Davezac et al. (2000) . As for CDC25C, the CDC25B phosphatase is able to associate with 14-3-3 proteins (Conklin et al., 1995; Mils et al., 2000) . Indeed the sequence surrounding serine 323 (in CDC25B3 numbering) residue, which corresponds to S216 in CDC25C, constitutes a major 14-3-3 binding site and S323 was shown to be absolutely necessary for 14-3-3 interaction (Forrest and Gabrielli, 2001; Mils et al., 2000) . 14-3-3 binding regulates the CDC25B activity (Escalas et al., 2000; Forrest and Gabrielli, 2001 ). The S323 residue was shown to play a crucial function in the G2 DNA-damage checkpoint. The overexpression of CDC25B mutant for S323 residue is even more effective than wild type CDC25B in overriding the G2 arrest (Forrest and Gabrielli, 2001 ). The S323 residue also plays a critical role for the regulation of subcellular localization of the protein, since it is required for cytoplasmic sequestration of CDC25B upon nucleo-cytoplasmic shuttling . Another aspect of CDC25B function is its involvement in microtubule nucleation at the centrosome as shown by overexpression experiments (Gabrielli et al., 1996) .
We recently described Xenopus pEg3 kinase, a new member of the KIN1/PAR-1/MARK family (Blot et al., 2002) . In Xenopus, pEg3 is a cell cycle dependent protein kinase. Phosphorylation and activity of pEg3 are regulated during the cell cycle. In synchronized cultured cells, phosphorylation of pEg3 is detected as early as the G2 phase and increases until mitosis. In early embryos pEg3 is maximally active during mitosis. These results suggested that pEg3 may play a role in cell cycle regulation. It was described that C-TAK1 associates with and phosphorylates CDC25C (Peng et al., 1998) . C-TAK1 and pEg3 both belong to the KIN1/PAR-1/MARK kinase family. The Kin1 kinase is involved in the control of cell morphology (Levin and Bishop, 1990) , PAR-1 in cell polarity (Guo and Kemphues, 1995) and MARK in microtubule dynamics (Drewes et al., 1997) . On the basis of sequence similarities between pEg3 and C-TAK1 on one hand, and the regulation of pEg3 during G2/M on the other hand, we hypothesized that pEg3 could interact and phosphorylate CDC25.
In this study we show that human pEg3 kinase specifically phosphorylates CDC25B in vitro and associates with CDC25B both in vivo and in vitro. Moreover, in human cells the expression of human pEg3 induces an accumulation of cells in the G2 phase. This effect is counteracted by overexpression of CDC25B. These results indicate that pEg3 is involved in cell cycle control and is a negative regulator of G2/ M progression. They also strongly support the fact that pEg3 has the opposite function to CDC25B.
Results

pEg3 expression in HeLa cells
The human KIAA0175 cDNA (Nagase et al., 1996) codes for a protein kinase sharing 65% identity with the overall sequence of Xenopus pEg3 protein (Blot et al., 2002, Figure 1a ). We will refer to the protein encoded by KIAA0175 cDNA as human pEg3. In Xenopus laevis, we have previously shown that pEg3 phosphorylation and activity are regulated during the cell cycle in embryos and in synchronized cultured somatic cells (Blot et al., 2002) . In order to examine pEg3 expression in human cells, a rabbit polyclonal serum (N4) was raised against the catalytic domain of the kinase. In exponentially growing HeLa cells, affinity purified N4 antibody detected several bands (Figure 1b, lane 1) . The band at 45 kDa and bands greater than 100 kDa are non-specific cross-reacting proteins. The band of 75 kDa exactly corresponded to the size calculated from pEg3 sequence. The corresponding pre-immune serum did not detect any protein in exponentially growing cells (Figure 1b, lane 6) . This band of 75 kDa co-migrated with the Xenopus pEg3 detected with the anti-Xenopus pEg3 L3 antibody in full-grown stage VI oocytes and exponentially growing Xenopus XTC cells (Figure 1b, lanes 4 and 5) . This result was expected, since human and Xenopus proteins contain exactly the same number of amino-acids ( Figure 1a) . In HeLa cells blocked in prometaphase with nocodazole, N4 antibody detected two bands having a reduced electrophoretic mobility ( Figure 1b, lane 2) . We have previously shown that phosphorylation of pEg3 in Xenopus eggs and embryos resulted in reduced electrophoretic mobility of the protein in polyacrylamide gel. These bands comigrated with pEg3 detected with L3 serum in Xenopus unfertilized eggs (Figure 1b, lane 3) . These results indicate that pEg3 is expressed in human cells and is probably phosphorylated in mitotic cells like the Xenopus protein.
Activity of recombinant human pEg3
The recombinant pEg3 kinase tagged with six histidine residues (FL) and the catalytically inactive kinase (FLK/R) obtained by replacing a conserved lysine by an arginine in the catalytic domain of pEg3 (see Materials and methods and Figure 2a) were produced in E. coli and purified on a nickel agarose affinity column. The results of the purifications are shown in Figure 2b (lanes 1 and 2) . The pEg3FLK/R appeared as a single fast migrating band whereas the full-length pEg3 kinase a potential cell cycle regulator N Davezac et al protein appeared as several retarded bands. A truncated version of pEg3 (DC) in which the conserved C-terminal domain is missing and its corresponding catalytically inactive mutant (pEg3DCK/R) were also produced and purified (Figure 2a ,b, lanes 3 and 4). As shown by Coomassie Blue staining, the pEg3DCK/R protein migrated as a single band like pEg3FLK/R but with a higher electrophoretic mobility. The difference in size corresponded to the deleted C-terminal domain. The pEg3DC protein migrated as fuzzy bands like pEg3FL, but with a higher electrophoretic mobility (Figure 2b , lane 3). These changes in electrophoretic mobility might be the consequence of phosphorylation. As shown in Figure 2c the electrophoretic mobilities of pEg3FLK/R and pEg3DCK/R were not changed after incubation with l-phosphatase. But the same treatment reduced pEg3FL and pEg3DC as a single fast migrating band at the same position as their respective K/R mutants, demonstrating that recombinant pEg3FL and pEg3DC are phosphorylated when expressed in E. coli. The kinase activity of these four purified recombinant proteins was tested in vitro. pEg3FL and pEg3DC were able to autophosphorylate (Figure 2d, lanes 1 and 3) . As expected pEg3FLK/R and pEg3DCK/R were catalytically inactive ( Figure 2d , lanes 2 and 4). We previously reported that the Xenopus pEg3 kinase is able to phosphorylate histone H1 in vitro (Blot et al., 2002) , we therefore tested the ability of the purified recombinant human pEg3 to use histone H1 as an in vitro substrate. Human pEg3FL and pEg3DC were able to phosphorylate histone H1 (Figure 2d , lanes 5 and 7) whereas pEg3FLK/R and pEg3DCK/R did not show detectable activity ( Figure  2d , lanes 6 and 8).
pEg3 specifically phosphorylates CDC25B phosphatases in vitro It was previously described that C-TAK1, a member of the KIN1/PAR-1/MARK kinase family, is able to . In order to compare the electrophoretic mobility of human and Xenopus pEg3, proteins of Xenopus unfertilized eggs (UFE), full-grown stage VI oocytes (VI) and cultured XTC cells (XTC) separated on the same 10% polyacrylamide gel were analysed by Western blotting with affinity purified anti-Xenopus pEg3 antibody (L3). The N4 pre-immune serum (PiN4) was also tested by Western blotting with protein extract of exponentially growing HeLa cells. Arrows and arrow heads indicate phosphorylated and hypophosphorylated pEg3, respectively pEg3 kinase a potential cell cycle regulator N Davezac et al associate with and to phosphorylate CDC25C phosphatase (Peng et al., 1998) . pEg3 presents a significant degree of sequence homology at the level of the catalytic domain with the C-TAK1 kinase (45% of identity, Figure 1a ). Thus we hypothesized that pEg3 might be able to phosphorylate CDC25. Figure 3a shows that recombinant human pEg3 specifically phosphorylated in vitro translated CDC25B but not CDC25A nor CDC25C although similar amounts of proteins were used. In human cells three splicing variants of CDC25B (B1-3) have been isolated (Baldin et al., 1997) . A kinase assay toward each of these splicing variants was performed. The three isoforms were translated in rabbit reticulocyte lysate, immunoprecipitated and incubated with recombinant pEg3 kinase (DC or DCK/R) in the presence of radioactive ATP in vitro. pEg3DC was used instead of pEg3FL because pEg3FL co-migrates with CDC25B in SDS -PAGE. The results presented in Figure 3b demonstrate that human pEg3 is able to phosphorylate the three variants of CDC25B without significant preference ( Figure 3b , lanes 2, 4 and 6). The control pEg3DCK/R clearly demonstrated that this phosphorylation was actually due to added recombinant pEg3 kinase. As shown above, pEg3 autophosphorylates and was also clearly detected ( Figure 3b , lane 8 and also 2, 4, 6). In vitro kinase assays were also performed using CDC25B3 fused to MBP (Maltose Binding Protein, (7) with lphosphatase, analysed by SDS -PAGE and stained with Coomassie G250. (d) To test the kinase activity of these proteins, purified recombinant proteins were incubated for 30 min at 308C in the absence (Autophosp.) or presence of histone H1 (H1) and radioactive ATP. After incubation, proteins were separated on a 12% (Autophosp.) and 18% (H1) polyacrylamide gel and autoradiographied pEg3 kinase a potential cell cycle regulator N Davezac et al MBP-CDC25B3) and pEg3FL. In this experiment 100 ng of MBP-CDC25B3 were incubated with increasing amounts of pEg3FL. The incorporation of radioactive phosphate increased until a plateau was reached for 250 ng of pEg3 ( Figure 3c ) clearly demonstrating that the CDC25B3 protein was stochiometrically phosphorylated by pEg3. However, no significant change in the phosphatase activity of MBP-CDC25B3 could be detected ( Figure 3d ). This result indicated that pEg3 does not regulate the activity of CDC25B in vitro. To determine which residue in CDC25B is phosphorylated by pEg3, three CDC25B3 mutants (S323G, S321G and S230G) were tested. These residues were selected because they are located in consensus 14-3-3 binding motifs. It was previously demonstrated that the C-TAK1 kinase phosphorylates S216 in CDC25C and creates a binding site for 14-3-3. Phosphorylation of S230G and S321G mutants was comparable to wild-type CDC25B3 (Figure 3e ) indicating that S230 and S321 are not phosphorylated by pEg3 in vitro. In contrast a 50% reduction in phosphorylation was observed in the case of S323G mutant. This could be the result in a structural modification of the mutated CDC25B. If this is the case this change must be minor since this mutant remains a substrate for CHK1 (Mils et al., 2000) . Thus these results strongly suggest that S323 is a target of pEg3. However, mutation of this residue did not completely abolish CDC25B3 phosphorylation indicating that pEg3 phosphorylates at least one additional amino-acid in CDC25B3 that remains to be identified. The 14-3-3 protein was previously shown to associate with CDC25B (Mils et al., 2000) . This association was not significantly modified by phosphorylation of CDC25B by pEg3 (data not shown). This result suggests that pEg3 does not regulate the association of CDC25B with 14-3-3 in vitro.
pEg3 specifically interacts with CDC25B in vitro Since pEg3 is able to specifically phosphorylate CDC25B it seemed possible that it could also physically interact with CDC25B. Co-immunoprecipitation experiments were performed to test this hypothesis. Because anti-human pEg3 antibody does not efficiently immunoprecipitate pEg3, we thought about using anti-Xenopus pEg3 (L2, Blot et al., 2002) . L2 serum was raised against a fragment of Xenopus pEg3 including C-terminal domain which is strongly conserved in human pEg3. The cross-reactivity of L2 antibody was tested by Western blotting using recombinant human pEg3 either full-length (FL) or deleted of the C-terminal domain (DC). The control pre-immune serum did not react against pEg3 ( (a) CDC25A, B and C produced in rabbit reticulocyte lysate in the presence of non-radioactive amino-acids were immunoprecipitated with specific antibodies and incubated in the presence of active pEg3 recombinant kinase (DC) and radioactive ATP for 30 min at 308C. Samples were separated on 8% SDS -PAGE and were subjected to autoradiography. The The specific phosphatase activity of CDC25B3 was measured before and after phosphorylation by pEg3FL and was expressed in arbitrary units (a.u.) . (e) In vitro translated wild-type or indicated mutant CDC25B3 protein were immunoprecipitated then incubated in the presence of pEg3DC for 30 min at 308C separated on 8% SDS -PAGE then subjected to autoradiography and analysed by Western blotting with antibodies raised against CDC25B. The 32 P incorporation was quantified and normalized to the amount of CDC25B3 protein. The indicated values are the average of three independent determinations pEg3 kinase a potential cell cycle regulator N Davezac et al
Immunoprecipitations were analysed by Western blotting with anti-human pEg3 N4 antibody. As shown in Figure 4a , pEg3FL was immunoprecipitated by L2 antibody (lane 8) but not with the corresponding preimmune serum (lane 7). Recombinant pEg3FL was immunoprecipitated with L2 serum. Immune complexes were adsorbed on protein A sepharose beads and then were incubated with CDC25A, B and C produced in rabbit reticulocyte lysate in the presence of radioactive methionine. The L2 pre-immune serum (Pi) was used as a control. As shown in Figure 4b , CDC25B was detected in L2 immunoprecipitates and traces are visible with the preimmune serum. However CDC25A and C were not detected in L2 immune complex. This experiment shows that pEg3 specifically interacted with the CDC25B phosphatase in vitro. This interaction may be direct or mediated by proteins of the rabbit reticulocyte lysate. To resolve this, a similar experiment was performed using purified GST-CDC25B3 produced in bacteria instead of programmed rabbit reticulocyte lysate and the GST protein was used as a control. Anti-GST antibodies detected GST-CDC25B in immunoprecipitates obtained with L2 serum (Figure 4c ). The GST protein alone was not detected in L2 immune complexes. These results show that the interaction between pEg3 and CDC25B is direct.
pEg3 interaction domain in CDC25B
The in vitro association assay was then used to map the pEg3 interaction domain on the CDC25B phosphatase. A set of N-terminal deletion mutants of CDC25B were produced in rabbit reticulocyte lysate and tested for their ability to interact with pEg3. Deletion of the 288 N-terminal residues of CDC25B did not abolish the interaction with pEg3 ( Figure 5 , lanes 9 to 16). However, the non specific signal detected with the control immunoprecipitate was suppressed when the 200 N-terminal residues were deleted from CDC25B. CDC25B was not detected any more when the 310 Nterminal residues were deleted ( Figure 5, lane 18) . This result indicates that in CDC25B, residues 288 -310 are necessary for pEg3 interaction and may represent the pEg3 interaction domain in CDC25B.
In vivo interaction between pEg3 and CDC25B
Since pEg3 is able to specifically interact with CDC25B in vitro, we tested if this interaction also occurred in vivo using the L2 antibody. Co-immunoprecipitation Figure 4 In vitro interaction between pEg3 and CDC25B. (a) Purified full-length recombinant pEg3 (FL) and pEg3 deleted of the C-terminal domain (DC) were analysed by Coomassie Blue staining (Coomassie). These proteins were analysed by Western blotting with anti-Xenopus pEg3 serum (L2) and the corresponding pre-immune serum (Pi). L2 and pre-immune sera were used to immunoprecipitate pEg3FL and immune complexes were analysed by Western blotting with anti-human pEg3 antibody (N4). Ig Hc: immunoglobulins heavy chains. (b,c) Purified recombinant pEg3FL protein (750 ng) or control buffer solution were subjected to immunoprecipitation with polyclonal antibodies against Xenopus pEg3 (L2) or with the corresponding pre-immune serum (Pi). (b) Interaction between pEg3 and the phosphatases CDC25A, B and C. Immune complexes were then incubated with in vitro translated 35 S labeled CDC25 A, B or C proteins (IVT) for 30 min at 48C. After washing, bound material was run on SDS -PAGE and visualized by autoradiography. An aliquot of the in vitro translation product (IVT) was also loaded as a control. (c) Purified recombinant pEg3FL protein (750 ng) was immunoprecipitated then incubated and processed as in (b) in the presence of 1 mg of recombinant GST or GST-CDC25B3 except that visualization of the interaction was performed by Western blotting using anti-GST antibodies. A sample of the GST preparation (GST) was also loaded as control Figure 5 Mapping of the interacting domain of pEg3 on CDC25B. Purified recombinant pEg3FL protein (750 ng) or control buffer solution was subjected to an immunoprecipitation with polyclonal antibodies against pEg3 (IP). The precipitates were then incubated in the presence of in vitro translated CDC25B wild-type or mutant proteins for 30 min at 48C. After washing, bound material was run on SDS -PAGE and visualized by autoradiography. Aliquots of the in vitro translation products were also loaded as control (IVT). Note that the non-specific interaction that is detected between in vitro translated CDC25B and the control immunoprecipitate vanished after deletion of the first 200 residues pEg3 kinase a potential cell cycle regulator N Davezac et al experiment was performed using anti-Xenopus L2 antibody and extracts from a human osteosarcoma cell line overexpressing HA-tagged CDC25B2 (U2OS-HA-CDC25B2) under the control of the tetracycline repressible promoter (Figure 6, lane 1) , or from control U2OS-Tet cells which do not overexpress CDC25B2 ( Figure 6, lane 2) . HA-CDC25B2 was present in L2 immunoprecipitate from U2OS-HA-CDC25B2 ( Figure  6 , lane 3) but was undetectable in immunoprecipitate made from U2OS-Tet control cells (Figure 6, lane 4) . However pEg3 was present in both immunoprecipitates (lanes 7 and 8). As expected, HA-CDC25B2 and pEg3 were not detected in immunoprecipitates made with L2 pre-immune serum (lanes 5, 6, 9 and 10). These experiments show that pEg3 and CDC25B phosphatases are able to interact in vivo.
The interaction of pEg3 with CDC25B was tested at different phases of the cell cycle using U2OS-HA-CDC25B2 cells treated with various drugs such as nocodazole and aphidicolin. No significant change in the pEg3/CDC25B interaction could be observed (data not shown).
The pEg3 kinase activity is regulated during the cell cycle
We examined the kinase activity of pEg3 immunoprecipitated from protein extracts of cells enriched in the different phases of cell cycle. We raised an antibody (M1) directed against part of the medium domain of the human pEg3. As expected M1 but not the corresponding pre-immune serum detected pEg3 in exponentially growing and prometaphase HeLa cells treated with nocodazole as fast and slow migrating bands, respectively (Figure 7a ). The pre-immune serum did not precipitate pEg3 whatever the phase of the cell cycle and the incorporation of radioactivity in histone H1 was low. In contrast the slow as well as the fast migrating pEg3 were immunoprecipitated with M1 serum from cells at the different phases of the cell cycle as shown by Western blotting using N4 purified antibody (Figure 7b, upper panel) . The pEg3 kinase activity was detected only for immunoprecipitations made with prometaphase arrested cells (Figure 7b , lower panel). As shown previously for the Xenopus pEg3 (Blot et al., 2002) , the kinase activity and phosphorylation of the human pEg3 are correlated and are maximum during mitosis. They are also correlated with the CDC25B phosphatase activity (Lammer et al., 1998) .
CDC25B expression counteracts the G2 accumulation induced by human pEg3 overexpression in cultured cells
In order to determine the possible role of human pEg3 in cell cycle control and the importance of CDC25B in this process, U2OS-HA-CDC25B2 and U2OS-Tet control cells were transiently transfected with plasmids allowing expression of pEg3FL and pEg3FLK/R tagged with the green fluorescent protein (GFP). The percentages of G1, S and G2/M cells were determined by FACS analysis. The cell distribution through the different phases of the cell cycle of untransfected U2OS-Tet and U2OS-HA-CDC25B2 cells were very Figure 6 In vivo interaction between pEg3 and CDC25B. Proteins (100 mg) extracted from U2OS-HA-CDC25B2 cells expressing HA-epitope tagged CDC25B2 (B2) under the control of the tetracycline repressible promoter and U2OS-Tet control cells (7) were analysed by Western blotting using anti-HA antibodies. Immunoprecipitations were performed using the anti-Xenopus pEg3 L2 serum and the corresponding pre-immune serum (Pi). Immune complexes were analysed by Western blotting with anti-HA (WB HA) and N4 (WB N4) antibodies to detect the presence of CDC25B2 and pEg3 proteins, respectively. In cells that do not express CDC25B2, two unrelated proteins are labeled with anti-HA (stars) Western blot analysis using specific antibody showed that HA-CDC25B2 expression was high in induced U2OS-HA-CDC25B2 cells and was not changed upon GFP-pEg3FL transfection (Figure 8g ). Similarly the amount of GFP-pEg3 FL was not modified by HA-CDC25B2 expression.
The accumulation of G2/M cells upon GFP-pEg3FL expression could reflect a decrease in CDC2 activity. Using p13 sepharose beads CDC2 was precipitated from 210 mg of proteins and detected with a specific antibody. In U2OS-HA-CDC25B2 cells expressing GFP-pEg3FL the amount of the fast migrating CDC2, which corresponds to the active kinase, was 72% of that in cells expressing HA-CDC25B2 only (Figure 8h ). This result indicated that CDC2 is kept inactivated when GFP-pEg3FL is expressed. But when GFP-pEg3FL and HA-CDC25B2 were co-expressed, the level of active CDC2 was increased back to 92%. Taken together these results indicate that the pEg3 kinase activity is necessary for G2 accumulation of cells and that CDC25B2 overexpression counteracts the effect of pEg3 expression, suggesting that pEg3 and CDC25B have antagonistic functions.
Discussion
We have previously reported that the Xenopus pEg3 protein is a cell cycle regulated kinase: phosphorylation and kinase activity of pEg3 are low during interphase and peak during mitosis (Blot et al., 2002) . In the present study, we show that ectopic expression of the human pEg3 promoted an accumulation of cells in the G2 phase of the cell cycle, suggesting that pEg3 is involved in the negative regulation of G2/M progression. This accumulation of cells in the G2 phase corresponds either to a delay or a blockage of the cell cycle. The CDC25B phosphatase is also involved in cell cycle progression. Microinjections of anti-CDC25B antibodies (Lammer et al., 1998) and overexpression of CDC25B inactive mutants (Gabrielli et al., 1996) demonstrated that CDC25B plays a role in the control of G2/M transition. Here we show that the overexpression of the CDC25B phosphatase counteracts the effect of pEg3 indicating that pEg3 and CDC25B may have antagonist functions. We cannot exclude the possibility that the pEg3-induced accumulation of cells in G2 is independent of CDC25B. Ectopic expression of pEg3 may arrest the cell cycle in G2 by an indirect mechanism. This may finally result in inhibition of the CDK1/cyclinB complex, the key regulator of the G2/M transition. Since CDC25B is an activator of the CDK1/cyclin B complex (Gabrielli et al., 1997) , then overexpression of CDC25B phosphatase would simply release this inhibition by activating the CDK1/cyclinB complex hence allowing mitosis to occur. However, we have shown that the human pEg3 protein kinase specifically associates with CDC25B in vitro and in vivo. Results of in vitro binding experiments indicate that human pEg3 directly interacts with CDC25B, no additional factor is required. The pEg3 association with CDC25B is stable during the cell cycle when HA-CDC25B2 expressing cells were synchronized with various drugs since no significant modification could be observed in cells treated with nocodazole or aphidicolin. Moreover, we have also shown that pEg3 is able to specifically phosphorylate the CDC25B phosphatase in vitro. Hence, the ectopic expression of pEg3 could perturb the cell cycle progression by interfering with the CDC25B function. This may occur either directly by phosphorylating CDC25B or indirectly by phosphorylating a protein which is also a substrate of CDC25B.
The expression of inactive pEg3FLK/R mutant does not induce the effect on cell cycle observed with the active kinase. This result indicates that the pEg3 kinase activity is necessary for G2 accumulation of cells. Since pEg3 is able to specifically phosphorylate CDC25B, we speculated that the G2 arrest might be due to CDC25B phosphorylation by pEg3. One can assume that CDC25B phosphatase activity could be decreased or abrogated upon phosphorylation by pEg3. However, in vitro, the phosphatase activity of CDC25B was not changed following phosphorylation by pEg3 which rules out this possibility. Whether this is also true in vivo toward specific substrates remains to be shown.
By the use of CDC25B mutants, we have shown that pEg3 phosphorylates CDC25B on serine 323 (S323) and on at least one additional unidentified residue. Truncated forms of CDC25B phosphatase bind to 14-3-3 proteins (Conklin et al., 1995; Mils et al., 2000) . The sequence surrounding S323 constitutes a major 14-3-3 binding site and S323 was shown to be absolutely necessary for 14-3-3 interaction (Forrest and Gabrielli, 2001; Mils et al., 2000) . It was recently suggested that 14-3-3 binding regulates the CDC25B activity (Forrest and Gabrielli, 2001 ). Overexpression of CDC25B in G2 checkpoint arrested cells overrides the DNA-damage induced G2 checkpoint. CDC25B mutated on S323 is even more effective than wild-type CDC25B (Forrest and Gabrielli, 2001) indicating that S323 plays a crucial function in the DNA-damage induced G2 checkpoint. The S323 residue is also essential for the cytoplasmic retention of CDC25B . Function of phosphorylation of the corresponding S323 residue in CDC25C (S216) is well documented although incompletely understood. In CDC25C, the S216 residue is the target of several kinases including CHK1, a kinase involved in DNA-damage checkpoint. The phosphorylation of S216 by CHK1 creates a binding site for 14-3-3. The binding of 14-3-3 to CDC25C regulates the subcellular localization of CDC25C and also regulates the phosphatase activity of CDC25C (Kumagai and Dunphy, 1999) . In vitro CHK1 is able to phosphorylate CDC25B (Mils et al., 2000; Sanchez et al., 1997) but not on the S323 residue and CHK1 was unable to promote CDC25B/14-3-3 interaction in vitro. Thus these results strongly suggested that CHK1 does not regulate this interaction (Mils et al., 2000) . Another kinase, C-TAK1, phosphorylates CDC25C on the S216 residue (Peng et al., 1998) . C-TAK1 phosphorylates CDC25C during interphase hence keeping it inactive. Interestingly C-TAK1 belongs to the KIN1/PAR-1/MARK family. One can speculate that pEg3 might regulate 14-3-3 binding or subcellular localization of CDC25B or both. However no change in subcellular localization of HA-CDC25B could be observed after transfection of cells with GFP-pEg3FL (data not shown). An important issue that should be explored is if the pEg3 kinase is involved in a checkpoint acting on CDC25B.
The CDC25B phosphatase has been shown to promote centrosome microtubule nucleation at prophase (Gabrielli et al., 1996) . The mechanism by which CDC25B acts in this process is not yet known, but it seems likely that it is mediated by the CDK1/ cyclinB complex (Gabrielli et al., 1996) . The pEg3 ectopic expression might interfere with microtubule nucleation, then delaying or stopping the cell cycle in G2. Overexpression of CDC25B would counteract the pEg3-induced G2 accumulation of cells via its microtubule nucleation promoting effect. Interestingly, the MARK1 and MARK2 kinases, two other members of the KIN1/PAR-1/MARK family, are involved in microtubule dynamics (Drewes et al., 1997) . Then it will be of importance to test whether pEg3 might be involved in microtubule stability.
Our previous work showed that the pEg3 kinase is regulated during the cell cycle. The present results show that pEg3 is involved in the control of cell cycle progression and very probably in the G2/M transition. The pEg3 protein belongs to the KIN1/PAR-1/MARK family of protein kinases which have a role in cell polarity and microtubule dynamics. Whether pEg3 is involved in cell polarity remains to be demonstrated but one possibility is that pEg3 may link the cell cycle with cell polarity and, or cell morphology via CDC25B phosphatase.
Materials and methods
Plasmids construction
Cloning of human pEg3 encoding KIAA0175 cDNA was previously described (Nagase et al., 1996) . This cDNA was cloned in pBluescript plasmid (pBluscript-Eg3). The coding sequence of KIAA0175 cDNA was amplified by PCR with primers 5'-GAGGGCTAGCAAAGATTATGAT-GAAC-3' (sense) which introduce a NheI restriction site pEg3 kinase a potential cell cycle regulator N Davezac et al and 5'-CCATCTCGAGTACCTTGCAGCTAGATAG-3' (antisense) which introduced a XhoI site. The KIAA0175 specific sequences are indicated in italics. All PCR were done using Pfu polymerase (Promega). The PCR product was digested with NheI and XhoI and cloned into NheI -XhoI sites in the pET21a vector (Invitrogene) giving the pET-Eg3FL plasmid. Lysine 40 was replaced by directed mutagenesis with a Transformer Site-Directed Mutagenesis kit according to the manufacturer's instructions (Clontech). Mutagenesis was realised on the pET-Eg3FL plasmid. For this purpose the following oligonucleotide was used: 5'-CTTACTGGAGAGATGGTcGCgATACGCATCATGGATAAAAACAC-3'. Bases corresponding to the arginine 40 residue are underlined and lower case letters indicate silent modifications used for introducing a NruI restriction site for selecting the mutagenized plasmid (pET-Eg3FLK/R). The C-terminal truncated pEg3 mutant was constructed by PCR on pBluescript-Eg3 plasmid with primers 5'-CGCGGATCCAAAGAT-TATGATGAACTTC-3' (sense) and 5'-CGGAATTCAT-TAACTTGTCTGTTCCTG-3' (antisense) introducing a BamHI and an EcoRI site, respectively. The PCR fragment was introduced into BamHI and EcoRI sites of pET21a vector giving the pET-Eg3DC plasmid. For constructing the pET-Eg3DCK/R plasmid the PCR was carried out using pET-Eg3FL K/R as the matrice and the PCR fragment was digested with BamHI and XmaI restriction enzymes. The same fragment was excised from pET-Eg3DC and replaced by the PCR fragment containing the K/R mutation. The following primers 5'-CGCGGATCCAAAGATTATGAT-GAACTTC-3' (sense) introducing a BamHI site and 5'-CGGAATTCAGAAGCAGAATGCTACTG-3' (antisense) introducing an EcoRI site were used to amplify a DNA fragment coding for a portion of the catalytic domain of pEG3 (AA 2 -240). This PCR product was cloned into BamHI -EcoRI sites of pET21a giving the pET21-Eg3N plasmid. A DNA fragment coding for part of the pEg3 medium domain (AA 338 -493) was obtained by PCR using the following primers 5'-CGCGGATCCTCCTGTGGA-CAAGCCAGTGC-3' (sense) and 5'-CGGAATTCATTAAC-TTGTCTGTTCCTG-3' (antisense) which introduce a BamHI site and a EcoRI site, respectively. The pET21-Eg3M plasmid was obtained by cloning this PCR product into BamHIEcoRI sites of pET21a.
To construct pEGFP-Eg3FL plasmid a DNA fragment was amplified by PCR from pBluescript-Eg3 using the following primers 5'-CGCGGATCCAAAGATTATGAT-GAACTTC-3' (sense) introducing a BamHI site and 5'-CGGAATTCACCTTGCAGCTAGATAGG-3' (antisense) introducing an EcoRI site. The PCR product was then introduced into BglII and EcoRI sites of pEGFP-C1 plasmid. The pEGFP-Eg3FL plasmid was constructed using the same strategy and same primers but pET-Eg3FL K/R was used as a matrice.
Human cDNA encoding the full length of CDC25 B1, B2 and B3, deletion mutants and point mutation of S323G were cloned in pET14b (Novagen) as described previously (Mils et al., 2000) . S321G and S230G mutations were generated by PCR mutagenesis on pET14b-CDC25 B3 plasmid using the following primers: 5'-GCGGCTCTTCCGGGGCCCGTCC-ATGCCCTG-3'; 5'-GCCCAGAGACCCGGGGGGGCCCC-CGACC-3' (sense) and 5'-CAGGGCATGGACGGGCCCC-GGAAGAGCCGC-3'; 5'-GGTCGGGGGCCCCCCCGGG-TCTCTGGGC-3' (antisense).
Construction of plasmid allowing expression of CDC25A was published previously (Molinari et al., 2000) . Davezac et al. will describe elsewhere the construction of plasmid allowing expression of CDC25C and MBP-CDC25B.
Expression and purification of recombinant proteins
Recombinant pET-Eg3FL, FLK/R, DC and DCK/R plasmids were transformed in E. coli strain BL21(DE3) pLys S. Expression and purification of native his-tagged pEg3 proteins were carried out following the manufacturer's recommendations (Qiagen Inc.). Proteins were eluted in IMAC buffer (20 mM Tris, 50 mM NaCl, 10% glycerol) containing 250 mM imidazol (Sigma). After purification proteins were kept in 50% glycerol at 7208C until use. For dephosphorylation experiment, 1 mg of the purified pEg3 proteins was incubated with 800 units of lambda phosphatase in the appropriate buffer (New England Biolabs) for one hour at 308C. Reaction was stopped by addition of Laemli sample buffer. Proteins were separated by SDS -PAGE and stained with Coomassie G250 (Biorad).
Preparation of antibodies and affinity purification
Recombinant N-terminal domain and medium domain of pEg3 (pEg3N and pEg3M, respectively) expressed in E. coli were purified and used to immunize rabbits (sera N4 and M1, respectively). Affinity purification of N4 immunoglobulins was performed by the membrane bound antigen method (Harlow and Lane, 1988) using the pEg3N recombinant protein. Anti-Xenopus pEg3 sera L2 and L3 have been described previously (Blot et al., 2002) . Antibodies against CDC25A, B and C (Santa-Cruz) and CDC2 (Oncogene Research) were used following the manufacturer's recommendations.
In vitro kinase assay
The activity of recombinant human pEg3 FL, FLK/R, DC and DCK/R proteins (250 ng) was tested with histone H1 as previously described for Xenopus pEg3 (Blot et al., 2002) . CDC25B protein was immunoprecipitated from 8 ml of in vitro translated with polyclonal rabbit antibodies anti-human CDC25B (raised against a C-terminal peptide) as described before (Baldin et al., 1997) . The immune complexes were incubated with 250 ng of recombinant human pEg3FL or truncated human pEg3DC in kinase buffer (50 mM Tris pH 7.5, 10 mM MgCl 2 , 25 mM NaCl, 1 mM DTT), 50 mM ATP and 5 mCi [g 32 P] ATP. The reaction was performed for 30 min at 308C and then stopped by the addition of 0.5 ml of lysis buffer. Samples were centrifuged and beads were resuspended in Laemli sample buffer. Proteins were separated by SDS -PAGE gel and analysed by autoradiography. The experiment was also performed with 100 ng of purified MBP-CDC25B3 and directly incubated with recombinant pEg3FL in the same conditions. The activity of pEg3 immunoprecipitated at the different phases of the cell cycle was tested in the same conditions except that 10 mCi of [g 32 P] ATP were used.
In vitro interaction
Wild-type and mutant forms of CDC25 were translated in vitro in rabbit reticulocyte lysate (TNT7 Quick, Promega) in the presence of 35 S-Methionine. Recombinant fusion protein GST-CDC25B or GST alone (Glutathione-S-Transferase) were expressed in E. coli and purified as already described (Baldin et al., 1997) . Recombinant pEg3FL protein (750 ng) was immunoprecipitated with the L2 antibody in lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, 50 mM NaF, 0.5% Triton-X100, 100 mM Na 3 VO 4 , 1 mM DTT) supplemented with protease inhibitors (1 mg/ml leupeptin, 1 mg/ml aprotipEg3 kinase a potential cell cycle regulator N Davezac et al nin, 10 mg/ml soybean trypsin inhibitor, 10 mg/ml tosyl lysine chloromethyl ketone (TLCK), 10 mg/ml tosyl phenylalanine chloromethyl ketone (TPCK), 0.17 mg/ml phenyl methyl sulfonyl fluoride (PMSF) and 10 mg/ml calpaine I), during 3 h at 48C, 50 ml of 1 : 5 Protein A Sepharose (Sigma) was added and the incubation was continued on for an additional 45 min. The immune complexes were washed three times with 1 ml lysis buffer and resuspended in 100 ml of the same buffer containing 5.5 ml of in vitro translated CDC25 B proteins or 5 mg of GST or GST-CDC25 B fusion proteins. After 1 h of incubation at 48C, the samples were centrifuged for 3 min at 734 g, then washed twice with the same buffer and twice with lysis buffer containing 250 mM NaCl. As a control, a similar procedure, in which recombinant pEg3 protein was omitted and pre-immune serum used, was followed. The precipitates were then subjected to SDS -PAGE analysis and autoradiography. When GST-CDC25 B fusion protein was used, the analysis was performed by Western-blotting using antibodies against GST (Pharmacia Biotech, 1/1000) and anti-Goat HRP (DAKO, 1/2500).
Cell culture and transfections
HeLa and Xenopus tadpole XTC cell lines were propagated in standard condition in Dulbecco's modified Eagle's medium (DMEM) and L-15 medium, respectively. U2OS-tTA (a generous gift of F Goubin) and derived cell lines were cultured in DMEM supplemented with 10% heat inactivated foetal calf serum (Eurobio), 2 mM glutamine, penicillin (100 U/ml), streptomycin (100 mg/ml), U2OS-HA CDC25B2 were cultured in the same media supplemented with hygromycin (200 mg/ml) and G418 (100 mg/ml) (Seromed). Establishment and characterization of the U2OS-tTA cell lines conditionally expressing CDC25B proteins will be described elsewhere (Theis-Febvre et al., in preparation). To turn off the expression of CDC25B, cells were maintained in presence of tetracycline (2 mg/ml). All the cell lines were grown at 378C in a humidified atmosphere containing 5% CO 2 .
Transient transfections were achieved using linear ethylenimin polymers (PEI, Exgen 500, Euromedex). One million cells were plated in 100 mm dishes and transfected the next day with 30 ml of Exgen 500 and 15 mg purified plasmids (pEGFP-Eg3FL or pEGFP-Eg3FLK/R). The medium was removed 2 h after and the cells were recovered for cell cycle analysis 24 h after transfection. As much as 50% of cells were transfected as determined by epifluorescence microscopic observations.
Co-immunoprecipitation
Cell pellets were resuspended in 3 -5 volumes of lysis buffer containing 1% NP40. The immunoprecipitations were performed using 10 ml polyclonal L2 antibodies raised against Xenopus pEg3 and its corresponding pre-immune serum during 4 h at 48C. Protein A Sepharose (50 ml of 1:5 dilution, Sigma) was added and the incubation was continued on for an additional hour. The samples were then washed twice with lysis buffer (without NP40) and twice with lysis buffer containing 250 mM NaCl. The immunoprecipitates were subjected to SDS -PAGE and Western blotting as previously described (Baldin et al., 1997) using monoclonal anti-HA antibody (12CA5, Roche Molecular Biomedicals). To immunoprecipitate pEg3, HeLa cells were lysed in the following buffer: 50 mM Tris pH 7.5, 150 mM NaCl, 1% NP40 supplemented with protease inhibitors (pepstatin, leupeptin, chymostatin and PMSF at 1 mg/ml each) 40 mM NaF, 40 mM b-glycerophosphate and 2.5 mM okadaic acid.
Flow cytometry analysis
HeLa cells synchronized in G1/S were obtained by addition of 10 mg/ml of aphidicholin in the culture medium during 15 h. Cells blocked by aphidicolin were released and harvested after 5 and 9 h to enrich the culture in S and G2 phase cells, respectively. Prometaphase cells were obtained by treatment with 500 ng/ml of nocodazole during 15 h. Percentages of cells in G1/S and G2/M were determined by FACS analysis using a Coulter Epics Flow Cytometer. To determine the mitotic index, cells were stained with Dapi and counted under the microscope. The GFP-pEg3FL or pEg3FLK/R over-expressing cells were detected on the basis of the GFP fluorescence. The data were collected using a FACS-Calibur (Becton Dickinson) flow cytometer and the quantification was performed using the ModFitLT software.
Miscellaneous methods
Xenopus stage VI oocytes and unfertilized eggs were obtained as previously described (Blot et al., 2002) . HeLa and XTC protein extracts used for Western blot analysis were obtained by cell lysis in Laemli sample buffer followed by heating at 958C for 5 min. Precipitation of CDC2 with p13 sepharose beads (Cans et al., 1999; Rice et al., 1997) and measurement of CDC25B phosphatase activity (Rice et al., 1997) were performed as previously described.
